My mum is in the late stages of Chronic Obstructive Pulmonary Disease (COPD), and watching her struggle for every breath is heartbreaking. Her condition has steadily worsened, and although there are medications available that could significantly improve her quality of life, they remain out of reach due to their exclusion from the Pharmaceutical Benefits Scheme (PBS). One such medication is Dupixent, known for its beneficial effects on reducing the frequency and severity of COPD flare-ups.

https://www.facebook.com/share/v/1Akkff3coj/

COPD is a debilitating and life-threatening condition that affects over 1.2 million Australians. It severely restricts the ability to breathe, making everyday activities a challenge. While treatments exist, not all are accessible or affordable, especially for those with limited financial means. Dupixent has shown promise in international studies, demonstrating an ability to lessen the symptoms of COPD, thus providing patients with a more manageable and dignified life.

The PBS plays a crucial role in keeping essential medications affordable for Australian citizens. Yet, the absence of Dupixent from this list means patients like my mum face both the physical burden of the disease and the financial strain of its treatment.

Including Dupixent on the PBS would not only offer financial relief but also provide hope and a possible improvement in the quality of life for many people with COPD. This action would symbolize a commitment to enabling all COPD patients to access the best possible care, regardless of their economic situation.

We call on the decision-makers to urgently evaluate and include Dupixent on the PBS. It is essential to extend the reach of this potentially life-changing medication to those who need it most. Please sign this petition to support thousands of Australians suffering from COPD and help bring Dupixent onto the PBS list.